Low-molecular polysulfated hyaluronic acid derivative and medicine containing same
A low-molecular-weight polysulfated hyaluronic acid derivative useful for treatment of an allergic disease. An agent for treatment of an allergic disease selected from pollinosis, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, and asthma, represented by the following general formula (IA) or (IB); wherein n represents a number of 0 to 15; R's each independently represent a hydrogen atom or an SO 3 H group etc.
1. A method for treating an allergic disease, the method comprising:
administering, to a human or an animal in need thereof, an effective dose of a low-molecular-weight polysulfated hyaluronic acid derivative of formula (IA) or (IB), or a pharmaceutically acceptable salt thereof:
wherein n is from 1 to 15;
X is of formula (a) or (b):
Y is of formula (c), (d), or (e):
each R is independently a hydrogen atom or an SO 3 H group, provided that SO 3 H groups account for from 80 to 100% of a total number of R groups;
R 1 is —OH, —OSO 3 H, or —NZ 1 Z 2 ;
Z 1 and Z 2 are each independently a hydrogen atom, —SO 3 H, an optionally substituted lower alkyl group, an optionally substituted aryl group, an optionally substituted aralkyl group, or an optionally substituted heteroaryl group, or —NZ 1 Z 2 is an amino acid residue or a peptide residue,
wherein when said lower alkyl group is substituted, the substituent is selected from the group consisting of a halogen atom, a carboxy group, an aryl group, a lower alkoxyl group, and an acyl group,
wherein when said aryl group is substituted, the substituent is selected from the group consisting of a halogen atom, a carboxy group, a lower alkyl group, a lower alkoxyl group, and an acyl group,
wherein when said aralkyl group is substituted, the substituent is selected from the group consisting of a halogen atom, a carboxy group, an aryl group, a lower alkoxyl group, an acyl group, and a lower alkyl group, and
wherein when said heteroaryl group is substituted, the substituent is selected from the group consisting of a halogen atom, a carboxy group, a lower alkyl group, a lower alkoxyl group, and an acyl group;
each * is a bonding site with an oxygen atom; and
W is of formula (f) or (g):
wherein the allergic disease is at least one selected from the group consisting of pollinosis, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, and asthma; and
wherein when X is (a), Y is not (c).
2. The method according to claim 1 , wherein Y in formula (IA) is of formula (d) or (e).
3. The method according to claim 2 , wherein X is of formula (a).
4. The method according to claim 3 , wherein n is 3, 4, or 5.
5. The method according to claim 3 , wherein n is 4 or 5.
6. The method according to claim 1 , wherein the low-molecular-weight polysulfated hyaluronic acid derivative is of formula (IB).
7. The method according to claim 6 , wherein n is 3, 4, or 5.
8. The method according to claim 6 , wherein n is 4 or 5.
9. A low-molecular-weight polysulfated hyaluronic acid derivative of formula (IA′) or (IB), or a pharmaceutically acceptable salt thereof:
wherein n is from 1 to 15;
X is of formula (a) or (b);
Y′ is of formula (d) or (e);
each R is independently a hydrogen atom or an SO 3 H group, provided that SO 3 H groups account for from 80 to 100% of a total number of R groups;
R 1 is —OH, —OSO 3 H, or —NZ 1 Z 2 ;
Z 1 and Z 2 are each independently a hydrogen atom, —SO 3 H, an optionally substituted lower alkyl group, an optionally substituted aryl group, an optionally substituted aralkyl group, or an optionally substituted heteroaryl group, or —NZ 1 Z 2 is an amino acid residue or a peptide residue,
wherein when said lower alkyl group is substituted, the substituent is selected from the group consisting of a halogen atom, a carboxy group, an aryl group, a lower alkoxyl group, and an acyl group,
wherein when said aryl group is substituted, the substituent is selected from the group consisting of a halogen atom, a carboxy group, a lower alkyl group, a lower alkoxyl group, and an acyl group,
wherein when said aralkyl group is substituted, the substituent is selected from the group consisting of a halogen atom, a carboxy group, an aryl group, a lower alkoxyl group, an acyl group, and a lower alkyl group, and
wherein when said heteroaryl group is substituted, the substituent is selected from the group consisting of a halogen atom, a carboxy group, a lower alkyl group, a lower alkoxyl group, and an acyl group;
each * is a bonding site with an oxygen atom; and
W is of formula (f) or (g):
10. The low-molecular-weight polysulfated hyaluronic acid derivative or pharmaceutically acceptable salt thereof according to claim 9 , wherein X is of formula (a).
11. The low-molecular-weight polysulfated hyaluronic acid derivative or pharmaceutically acceptable salt thereof according to claim 9 , wherein the low-molecular-weight polysulfated hyaluronic acid derivative is of formula (TB).
12. The low-molecular-weight polysulfated hyaluronic acid derivative or pharmaceutically acceptable salt thereof according to claim 10 , wherein n is 3, 4, or 5.
13. A pharmaceutical composition, comprising:
the low-molecular-weight polysulfated hyaluronic acid derivative or pharmaceutically acceptable salt thereof according to claim 9 , and
a pharmaceutically acceptable excipient.
14. The low-molecular-weight polysulfated hyaluronic acid derivative or pharmaceutically acceptable salt thereof according to claim 11 , wherein n is 3, 4, or 5.
15. A pharmaceutical composition, comprising:
the low-molecular-weight polysulfated hyaluronic acid derivative or pharmaceutically acceptable salt thereof according to claim 10 , and
a pharmaceutically acceptable excipient.
16. A pharmaceutical composition, comprising:
the low-molecular-weight polysulfated hyaluronic acid derivative or pharmaceutically acceptable salt thereof according to claim 11 , and
a pharmaceutically acceptable excipient.
17. A pharmaceutical composition, comprising:
the low-molecular-weight polysulfated hyaluronic acid derivative or pharmaceutically acceptable salt thereof according to claim 12 , and
a pharmaceutically acceptable excipient.
18. A pharmaceutical composition, comprising:
the low-molecular-weight polysulfated hyaluronic acid derivative or pharmaceutically acceptable salt thereof according to claim 14 , and
a pharmaceutically acceptable excipient.
19. The method according to claim 1 , wherein X is (b) and Y is of formula (c), (d), or (e).
20. The method according to claim 1 , wherein X is (a) or (b) and Y is of formula (d) or (e).